Pulling the network together: Quasiexperimental trial of a patient-defined support network intervention for promoting engagement in HIV care and medication adherence on mfangano Island, Kenya

Journal of Acquired Immune Deficiency Syndromes

Volumn 69, Issue 4, 2015, Pages e127-e134

  Hickey, Matthew D ^a,b,c   Salmen, Charles R ^b,c,d   Omollo, Dan ^b   Mattah, Brian ^b   Fiorella, Kathryn J ^b,e   Geng, Elvin H ^a   Bacchetti, Peter ^a   Blat, Cinthia ^a   Ouma, Gor B ^b   Zoughbie, Daniel ^c   Tessler, Robert A ^a   Salmen, Marcus R ^b   Campbell, Harold ^b,c   Gandhi, Monica ^a   Shade, Starley ^f   Njoroge, Betty ^g   Bukusi, Elizabeth A ^g   Cohen, Craig R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Mfangano Island Research Group Organic Health Response   (Kenya)

^c Microclinic International   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

Adherence; HIV AIDS; Kenya; Retention in care; Social network; Stigma

Indexed keywords

NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG HAIR LEVEL; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KENYA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MICROCLINIC; PATIENT CARE; PATIENT COUNSELING; PATIENT PARTICIPATION; PRIORITY JOURNAL; QUASI EXPERIMENTAL STUDY; SOCIAL NETWORK; SOCIAL SUPPORT; SUPPORT GROUP; COMMUNITY CARE; HIV INFECTIONS; MIDDLE AGED; PSYCHOLOGY; THEORETICAL MODEL;

ADULT; ANTI-HIV AGENTS; COMMUNITY HEALTH SERVICES; FEMALE; HIV INFECTIONS; HUMANS; KENYA; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MODELS, THEORETICAL; SOCIAL SUPPORT;

EID: 84964698158     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000000664     Document Type: Article

References (41)

1. WHO. Global Update on HIV Treatment 2013: Results, Impact and Opportunities. Geneva, Switzerland: World Health Organization; 2013.
2. Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health. 2010;15(suppl 1):1-15.
3. Geng EH, Glidden DV, Bwana MB, et al. Retention in care and connection to care among HIV-infected patients on antiretroviral therapy in Africa: estimation via a sampling-based approach. PLoS One. 2011;6:e21797.
4. Merten S, Kenter E, McKenzie O, et al. Patient-reported barriers and drivers of adherence to antiretrovirals in sub-Saharan Africa: a meta-ethnography. Trop Med Int Health. 2010;15(suppl 1):16-33.
5. Ware NC, Idoko J, Kaaya S, et al. Explaining adherence success in sub-Saharan Africa: an ethnographic study. PLoS Med. 2009;6:e11.
6. Watt MH, Maman S, Earp JA, et al. "It's all the time in my mind": facilitators of adherence to antiretroviral therapy in a Tanzanian setting. Soc Sci Med. 2009;68:1793-1800.
7. Salmen C. Towards an Anthropology of Organic Health: The Relational Fields of HIV/AIDS Among the Suba of Lake Victoria: Institute of Social and Cultural Anthropology. Oxford University; 2009.
8. Greeff M, Phetlhu R, Makoae LN, et al. Disclosure of HIV status: experiences and perceptions of persons living with HIV/ADS and nurses involved in their care in Africa. Qual Health Res. 2008;18:311-324.
9. Tsai AC, Bangsberg DR, Kegeles SM, et al. Internalized stigma, social distance, and disclosure of HIV seropositivity in rural Uganda. Ann Behav Med. 2013;46:285-294.
10. Mbonu NC, van den Borne B, De Vries NK. Stigma of people with HIV/ADS in sub-Saharan Africa: a literature review. J Trop Med. 2009; 2009:145891.
11. Simbayi LC, Kalichman S, Strebel A, et al. Internalized stigma, discrimination, and depression among men and women living with HIV/ADS in Cape Town, South Africa. Soc Sci Med. 2007;64: 1823-1831.
12. Turan JM, Hatcher AH, Medema-Wijnveen J, et al. The role of HIV-related stigma in utilization of skilled childbirth services in rural Kenya: a prospective mixed-methods study. PLoS Med. 2012;9:e1001295.
13. Katz IT, Ryu AE, Onuegbu AG, et al. Impact of HIV-related stigma on treatment adherence: systematic review and meta-synthesis. J Int AIDS Soc. 2013;16(3 suppl 2):18640.
14. Kunutsor S, Walley J, Katabira E, et al. Improving clinic attendance and adherence to antiretroviral therapy through a treatment supporter intervention in Uganda: a randomized controlled trial. AIDS Behav. 2011;15:1795-1802.
15. Stubbs BA, Micek MA, Pfeiffer JT, et al. Treatment partners and adherence to HAART in Central Mozambique. AIDS Care. 2009;21:1412-1419.
16. Idoko JA, Agbaji O, Agaba P, et al. Direct observation therapy-highly active antiretroviral therapy in a resource-limited setting: the use of community treatment support can be effective. Int J STD AIDS. 2007;18:760-763.
17. Fatti G, Meintjes G, Shea J, et al. Improved survival and antiretroviral treatment outcomes in adults receiving community-based adherence support: 5-year results from a multicentre cohort study in South Africa. J Acquir Immune Defic Syndr. 2012;61:e50-e58.
18. Nachega JB, Chaisson RE, Goliath R, et al. Randomized controlled trial of trained patient-nominated treatment supporters providing partial directly observed antiretroviral therapy. AIDS. 2010;24:1273-1280.
19. Pearson CR, Micek MA, Simoni JM, et al. Randomized control trial of peer-delivered, modified directly observed therapy for HAART in Mozambique. J Acquir Immune Defic Syndr. 2007;46:238-244.
20. Taiwo BO, Idoko JA, Welty LJ, et al. Assessing the viorologic and adherence benefits of patient-selected HIV treatment partners in a resource-limited setting. J Acquir Immune Defic Syndr. 2010;54:85-92.
21. Luque-Fernandez MA, Van Cutsem G, Goemaere E, et al. Effectiveness of patient adherence groups as a model of care for stable patients on antiretroviral therapy in Khayelitsha, Cape Town, South Africa. PLoS One. 2013;8:e56088.
22. Wouters E, Van Damme W, Van Loon F, et al. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome. Soc Sci Med. 2009;69:1177-1185.
23. O'Laughlin KN, Wyatt MA, Kaaya S, et al. How treatment partners help: social analysis of an African adherence support intervention. AIDS Behav. 2012;16:1308-1315.
24. Ding E, Prescott M, Watson KT, et al. Microclinic social network lifestyle intervention for weight loss and obesity management: a 10 month randomized controlled trial. Paper presented at: American Heart Association annual meeting; November 18, 2013; Dallas, TX.
25. Zoughbie DE. Community-based diabetes programme: the micro-clinic project. East Mediterr Health J. 2009;15:1021-1026.
26. Prescott M, Zoughbie D, Watson K, et al. The Microclinic Health Program: a social network-based intervention for weight loss and diabetes risk management. Am J Epidemiol. 2013;177(11 suppl):S1-S181.
27. Zoughbie D, Watson K, Bui N, et al. Long-term bodyweight and glucose management effects of the Microclinic Social Network Health Behavioral Program in Amman, Jordan: 2-year results. Paper presented at: Fifth Annual CUGH Conference; May 12, 2014; Washington, DC.
28. Bangsberg DR, Deeks SG. Spending more to save more: interventions to promote adherence. Ann Intern Med. 2010;152:54-56; W-13.
29. County HIV Service Delivery Profiles. Ministry of Health, Republic of Kenya; 2013.
30. Visser MJ, Kershaw T, Makin JD, et al. Development of parallel scales to measure HIV-related stigma. AIDS Behav. 2008;12:759-771.
31. Carey MP, Schroder KE. Development and psychometric evaluation of the brief HIV Knowledge Questionnaire. AIDS Educ Prev. 2002;14:172-182.
32. Broadhead WE, Gehlbach SH, de Gruy FV, et al. The Duke-UNC Functional Social Support Questionnaire. Measurement of social support in family medicine patients. Med Care. 1988;26:709-723.
33. Hickey MD, Salmen CR, Tessler RA, et al. Antiretroviral concentrations in small hair samples as a feasible marker of adherence in rural Kenya. J Acquir Immune Defic Syndr. 2014;66:311-315.
34. Huang Y, Yang Q, Yoon K, et al. Microanalysis of the antiretroviral nevirapine in human hair from HIV-infected patients by liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem. 2011; 401:1923-1933.
35. Huang Y, Gandhi M, Greenblatt RM, et al. Sensitive analysis of anti-HIV drugs, efavirenz, lopinavir and ritonavir, in human hair by liquid chromatography coupled with tandem mass spectrometry. Rapid Commun Mass Spectrom. 2008;22:3401-3409.
36. Baxi S, Greenblatt R, Bacchetti P, et al. Nevirapine concentrations in hair is a strong predictor of virologic suppression and toxicities (MOPE038). Paper presented at: 20th International AIDS Conference; July 20-25, 2014; Melbourne, Australia; (manuscript in submission).
37. Satagopan JM, Ben-Porat L, Berwick M, et al. A note on competing risks in survival data analysis. Br J Cancer. 2004;91:1229-1235.
38. Gandhi M, Ameli N, Bacchetti P, et al. Atazanavir concentration in hair is the strongest predictor of outcomes on antiretroviral therapy. Clin Infect Dis. 2011;52:1267-1275.
39. Decroo T, Van Damme W, Kegels G, et al. Are expert patients an untapped resource for ART provision in Sub-Saharan Africa? AIDS Res Treat. 2012;2012:749718.
40. Ware NC, Wyatt MA, Geng EH, et al. Toward an understanding of disengagement from HIV treatment and care in sub-Saharan Africa: a qualitative study. PLoS Med. 2013;10:e1001369.
41. Kranzer K, Ford N. Unstructured treatment interruption of antiretroviral therapy in clinical practice: a systematic review. Trop Med Int Health. 2011;16:1297-1313.